REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Study WX-20-002 will confirm diagnostic efficacy and safety of a PET/CT scan using Iodine
(124I) Girentuximab performed during the diagnostic work-up in patients with indeterminate
cT1-renal masses.